Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,328 active trials222 approved drugs2,775 evidence items
- NCIt
- C4741
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,686 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06065007 | Quality of Life and Disease-related Symptoms in Individuals With Systemic Mastocytosis | active not recruiting | — | 400 | Uppsala UniversityOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03376672 | Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients | active not recruiting | Phase 2 | 120 | Raija SilvennoinenOTHER | 4 | Apr 3, 2025 | clinicaltrials |
| NCT03480334 | Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy(AERN) | active not recruiting | Phase 2 | 26 | University of CologneOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT03498378 | Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 | 24 | Kathryn GoldOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT04164901 | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) | active not recruiting | Phase 3 | 331 | Institut de Recherches Internationales ServierOTHER | 11 | Apr 3, 2025 | clinicaltrials |
| NCT06900283 | Quality of Life as a Predictor of OS and PFS in Patients With Lung Cancer(FACT-L_Pred) | active not recruiting | — | 320 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 1 | Apr 3, 2025 | clinicaltrials |
| NCT03918655 | MIF Involvement in AML(MIFAML) | active not recruiting | — | 186 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT04517214 | Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT04688697 | Prepectoral and Subpectoral Implant-based Breast Reconstruction | active not recruiting | N/A | 300 | Fudan UniversityOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT04711109 | Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation(BRCA-P) | active not recruiting | Phase 3 | 300 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05252988 | Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib(DIANER) | active not recruiting | Phase 2 | 177 | Spanish Breast Cancer Research GroupOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05753995 | Immuno-Positron Emission Tomography (PET)-Glioma Study, a Proof-of-principle Imaging Study | active not recruiting | N/A | 20 | Kepler University HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT02170090 | Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer(ACTICCA-1) | active not recruiting | Phase 3 | 789 | Universitätsklinikum Hamburg-EppendorfOTHER | 8 | Mar 30, 2025 | clinicaltrials |
| NCT04420754 | Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer | active not recruiting | Phase 1 | 70 | AffyImmune Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2025 | clinicaltrials |
| NCT03772899 | Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic) | active not recruiting | Phase 1 | 20 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04392037 | Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone(ICON) | active not recruiting | Phase 2 | 60 | Amsterdam UMC, location VUmcOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT03460067 | Omission of Radiation in Patients With Her-2 Positive Breast Cancer | active not recruiting | N/A | 12 | University of Kansas Medical CenterOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT04296175 | Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)(CITRINE) | active not recruiting | Phase 3 | 808 | Fudan UniversityOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT05034497 | Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases(ReSPECT-LM) | active not recruiting | Phase 1 | 18 | Plus TherapeuticsINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT02818829 | Biological and Clinical Database for Pancreatic Adenocarcinoma(BACAP) | active not recruiting | — | 1,700 | University Hospital, ToulouseOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT04962126 | Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy(FLUORO) | active not recruiting | Phase 2 | 15 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05304468 | Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain | active not recruiting | Phase 3 | 452 | Sun Yat-sen UniversityOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05623787 | Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms(DWI-HighRisk) | active not recruiting | N/A | 30 | Laval UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05883956 | A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia(PREFER-HMA) | active not recruiting | Phase 3 | 13 | Otsuka Australia Pharmaceutical Pty LtdINDUSTRY | 2 | Mar 20, 2025 | clinicaltrials |
| NCT06886763 | HCC Innervation Assessment | active not recruiting | — | 300 | Hospices Civils de LyonOTHER | 2 | Mar 20, 2025 | clinicaltrials |
| NCT06396611 | Exercise As Intervention in Chronic Lymphocytic Leukemia(ADRENALINE) | active not recruiting | N/A | 11 | Universidade do PortoOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT03496402 | Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)(MICCHADO) | active not recruiting | N/A | 600 | Institut CurieOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT04717700 | Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients(SABLe) | active not recruiting | Phase 2 | 50 | Ida Bruun KristensenOTHER | 3 | Mar 18, 2025 | clinicaltrials |
| NCT06881225 | Regulation of Blood-Brain Barrier Permeability by APOE Gene Polymorphism and Its Impact on Cognitive Function Post-Radiotherapy in Nasopharyngeal Carcinoma: An MRI Study | active not recruiting | — | 300 | Sun Yat-sen UniversityOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT05612477 | Blood Salvage in Orthotopic Liver Transplantation With HCC(SOLT) | active not recruiting | N/A | 30 | University Health Network, TorontoOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT06707025 | The Expression of CD24 "do-not-eat-me" Signal in Cholangiocarcinoma(CD24CCA) | active not recruiting | — | 50 | Hadassah Medical OrganizationOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT04632433 | Neoadjuvant Plus Adjuvant Treatment With Cemiplimab in Cutaneaous Squamous Cell Carcinoma | active not recruiting | Phase 2 | 25 | Fondazione Melanoma OnlusOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT06054529 | Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients(GBM-FLUX2) | active not recruiting | — | 2 | AdventHealth Translational Research InstituteOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05844150 | A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC | active not recruiting | Phase 2 | 50 | Biotheus Inc.INDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04246203 | Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer(PROJECTION) | active not recruiting | — | 200 | Ludwig-Maximilians - University of MunichOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT05918133 | A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | active not recruiting | Phase 1 / Phase 2 | 42 | Biotheus Inc.INDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06868758 | Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer | active not recruiting | — | 50 | Chongqing General HospitalOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT05736523 | Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA) | active not recruiting | — | 28 | University of UtahOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06863818 | Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs | active not recruiting | — | 30 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06863870 | Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma | active not recruiting | — | 35 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT05913037 | FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas | active not recruiting | Phase 3 | 167 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04223024 | Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 246 | Sun Yat-sen UniversityOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04980885 | A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03452579 | Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM | active not recruiting | Phase 2 | 90 | David PeereboomOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04807192 | CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC) | active not recruiting | Phase 2 | 40 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05732805 | A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma(OCTAVA) | active not recruiting | Phase 3 | 270 | BiocadINDUSTRY | 3 | Feb 27, 2025 | clinicaltrials |
| NCT06748495 | Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer | active not recruiting | — | 600 | Hunan Cancer HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06850506 | Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment | active not recruiting | — | 70 | Peking University People's HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Apr 4, 2025source: clinicaltrials